IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.414
AS - Asia 1.379
EU - Europa 1.130
SA - Sud America 216
Continente sconosciuto - Info sul continente non disponibili 102
AF - Africa 93
OC - Oceania 6
Totale 5.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.348
CN - Cina 490
SG - Singapore 340
IE - Irlanda 315
VN - Vietnam 189
IT - Italia 164
HK - Hong Kong 163
BR - Brasile 161
RU - Federazione Russa 153
DE - Germania 134
FI - Finlandia 103
ZA - Sudafrica 74
FR - Francia 66
GB - Regno Unito 57
IN - India 56
CA - Canada 32
BD - Bangladesh 26
JP - Giappone 26
SE - Svezia 25
PL - Polonia 19
CO - Colombia 17
ES - Italia 15
NL - Olanda 14
AT - Austria 13
MX - Messico 13
AR - Argentina 12
IQ - Iraq 12
TR - Turchia 10
LT - Lituania 9
PK - Pakistan 8
SA - Arabia Saudita 8
CL - Cile 7
ID - Indonesia 7
AU - Australia 6
PH - Filippine 6
VE - Venezuela 6
AL - Albania 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
BO - Bolivia 4
EC - Ecuador 4
EG - Egitto 4
GR - Grecia 4
TN - Tunisia 4
AZ - Azerbaigian 3
DK - Danimarca 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
LV - Lettonia 3
MA - Marocco 3
NI - Nicaragua 3
PT - Portogallo 3
UA - Ucraina 3
AM - Armenia 2
BG - Bulgaria 2
HR - Croazia 2
HT - Haiti 2
IL - Israele 2
KE - Kenya 2
KR - Corea 2
LB - Libano 2
LU - Lussemburgo 2
MN - Mongolia 2
MU - Mauritius 2
MY - Malesia 2
PE - Perù 2
UY - Uruguay 2
UZ - Uzbekistan 2
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HN - Honduras 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 5.236
Salva come PNG Salva come JPEG
Città #
Dublin 313
San Jose 270
Ashburn 229
Chandler 208
Dallas 194
Singapore 192
Hong Kong 157
Beijing 146
Council Bluffs 138
Los Angeles 81
Helsinki 77
Boardman 76
Ho Chi Minh City 73
Johannesburg 70
Nanjing 55
New York 55
Munich 49
Lauterbourg 45
Hanoi 43
Princeton 37
Shanghai 36
Lawrence 34
Medford 33
Santa Clara 32
Pavia 27
Milan 26
Wilmington 26
Tokyo 24
Moscow 21
Nanchang 21
Jacksonville 20
Orem 20
Redondo Beach 19
São Paulo 19
Buffalo 18
Chennai 18
Montreal 17
Changsha 16
Chicago 16
Warsaw 16
Atlanta 15
Piscataway 15
Shenyang 15
Da Nang 14
Hebei 14
Turku 14
Nuremberg 13
Tianjin 13
Denver 12
San Francisco 12
Frankfurt am Main 10
Haiphong 10
Houston 10
Jiaxing 10
Phoenix 10
Poplar 10
Stockholm 10
Brooklyn 9
Falkenstein 9
London 9
Seattle 9
Amsterdam 8
Ankara 8
Norwalk 8
Pune 8
Vienna 8
Columbus 7
Hangzhou 7
Hải Dương 7
Manchester 7
Rome 7
Toronto 7
Brasília 6
Cagliari 6
Catania 6
Mexico City 6
Rio de Janeiro 6
Tamm 6
The Dalles 6
Woodbridge 6
Fairfield 5
Florence 5
Hyderabad 5
Newark 5
Padua 5
Redwood City 5
Tirana 5
Washington 5
Baghdad 4
Bexley 4
Boston 4
Brussels 4
Charlotte 4
City of London 4
Dubai 4
Medellín 4
Queens 4
Riyadh 4
Agawam 3
Amman 3
Totale 3.426
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 221
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 148
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 144
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 137
A patient with AL amyloidosis with negative free light chain results 134
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 131
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 130
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 129
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 126
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 121
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 121
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 118
Prognostication of survival and progression to dialysis in AA amyloidosis 118
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 115
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 115
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 114
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 110
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 109
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 107
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 107
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 104
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 104
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 102
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 99
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 99
A case of monoclonal gammopathy of renal significance 98
Development and Validation of Staging Systems for AA Amyloidosis 95
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 94
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 93
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 90
The lung in amyloidosis 89
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 88
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 88
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 86
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 84
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 83
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 83
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 79
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 79
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 77
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 77
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 77
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 77
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 75
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 73
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 66
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 66
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 63
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 63
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 62
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 55
Renal amyloidoses 42
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study 35
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis 34
null 33
null 30
null 29
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS 8
null 6
Totale 5.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022151 0 0 0 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025864 27 57 9 28 10 75 79 35 210 50 107 177
2025/20262.301 147 149 193 308 319 85 389 144 253 142 69 103
2026/2027593 175 110 134 174 0 0 0 0 0 0 0 0
Totale 5.340